Skip to main content
AYTU
NASDAQ Life Sciences

Aytu Posts Q1 FY2027 Revenue of $14.8M, Skips Earnings Call Ahead of $2.70/Share Rosemont Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.82
Mkt Cap
$19.78M
52W Low
$1.75
52W High
$3.065
52W Position info
4.0% above low
Off High info
41% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

AYTU is trading near its 52-week low of $1.75 (4.0% above the low).

Summary

Aytu reported Q1 FY2027 revenue of $14.8M, up 6.9%, with EXXUA at $4.9M and a ($3.9)M net loss, and skipped its earnings call due to the pending $2.70-per-share Rosemont merger.


Key Events · Earnings and Guidance · AYTU

  • Q1 FY2027 Revenue Up 6.9%

    Net revenue was $14.8 million versus $13.9 million a year earlier, with gross profit of $9.4 million, or 63.6% of revenue.

  • EXXUA Growth Offsets ADHD Decline

    EXXUA net revenue reached $4.9 million, up 24.5% from $3.9 million in Q4 FY2026, on 4,400 prescriptions (+32.5% sequentially), while the ADHD portfolio fell to $7.7 million from $13.2 million on generic competition for Adzenys XR-ODT.

  • Net Loss Widens to ($3.9)M

    Net loss was ($3.9) million, or ($0.20) per share, versus net income of $2.0 million a year earlier; Adjusted EBITDA was ($2.6) million versus ($0.6) million.

  • Cash Slips to $25.5M

    Cash and cash equivalents were $25.5 million at September 30, 2026, down from $26.3 million at June 30, 2026, with $0.3 million used in operating activities.


Analysis · AYTU · Life Sciences

With the merger terms already public, the fresh information here is the quarterly numbers. Revenue rose 6.9% to $14.8M, but the mix shifted sharply: EXXUA grew 24.5% sequentially to $4.9M while the ADHD portfolio fell to $7.7M from $13.2M as promotional spend moved to EXXUA and generics hit Adzenys XR-ODT. The bottom line swung to a ($3.9)M net loss from $2.0M of income a year ago, and Adjusted EBITDA worsened to ($2.6)M from ($0.6)M. Against a $2.70 all-cash tender offer, the $25.5M of cash means operating results matter less to the share price than deal completion, but they show the EXXUA ramp that underpins the $56M fully-diluted valuation. The company also canceled its earnings call because of the pending merger.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AYTU was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $1.75 to $3.07. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AYTU - Latest Insights

AYTU
Nov 16, 2026, 4:26 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.82 info
Change: $0 (0%) info
Market Cap: $19.78M info
AYTU
Nov 16, 2026, 4:01 PM EST
Source: ACCESS Newswire
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.82 info
Change: $0 (0%) info
Market Cap: $19.78M info
AYTU
Sep 22, 2026, 4:14 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.34
Real-time Price: $1.82 info
Change: -$0.520 (-22%) info
Market Cap: $19.78M info
AYTU
Sep 22, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.26
Real-time Price: $1.82 info
Change: -$0.4401 (-19%) info
Market Cap: $19.78M info
AYTU
Sep 22, 2026, 4:05 PM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $2.35
Real-time Price: $1.82 info
Change: -$0.530 (-23%) info
Market Cap: $19.78M info